Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
The Food and Drug Administration (FDA) is advising consumers to not buy or use Sit and Slim II, a product promoted and sold for weight loss.
An FDA analysis confirmed that Sit and Slim II contains sibutramine, a controlled substance that was removed from the market in October 2010 due to safety concerns. Sibutramine is known to substantially increase blood pressure and/or pulse rate in some patients and may pose a significant risk in patients with a history of coronary artery disease, congestive heart failure, arrhythmias, or stroke.
RELATED: Temperature Excursions Lead to Vancomycin Injection Recall
The FDA analysis also confirmed that Sit and Slim II contains phenolphthalein, a chemical not present as an active ingredient in the U.S. Studies have shown that it presents a cancer-causing risk.
Sit and Slim II is sold on various websites and in some retail stores.
For more information call (800) 332-1088 or visit FDA.gov.
